Cellectar Biosciences INC NEW
CLRB
CLRB: Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
moreShow CLRB Financials
Recent trades of CLRB by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CLRB's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells Oct. 11, 2022
-
Patent Title: Phospholipid ether analogs as cancer-targeting drug vehicles Sep. 13, 2022
-
Patent Title: Phospholipid ether analogs as cancer-targeting drug vehicles Mar. 27, 2018
-
Patent Title: Fluorescent phospholipid ether compounds, compositions, and methods of use Apr. 11, 2017
-
Patent Title: Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof Feb. 28, 2017
-
Patent Title: Phospholipid analogs as diapeutic agents and methods thereof Jan. 24, 2017
-
Patent Title: Phospholipid ether analogs as cancer-targeting drug vehicles Nov. 01, 2016
-
Patent Title: Phospholipid ether analogs as cancer-targeting drug vehicles May. 24, 2016
Federal grants, loans, and purchases
Followers on CLRB's company Twitter account
Number of mentions of CLRB in WallStreetBets Daily Discussion
Recent insights relating to CLRB
Recent picks made for CLRB stock on CNBC
ETFs with the largest estimated holdings in CLRB
Flights by private jets registered to CLRB